Teva Pharmaceutical Indus (TEVA) Stock Price, Quote, News & History | Benzinga

Teva Pharmaceutical Industries Ltd (TEVA) Stock Price, Quote, News & History

TEVANYSE

Trade with Public

Trade with Public

$36.52

-0.22-0.6%

At close: Aug 13, 5:00 PM EST

$36.40

-0.12-0.33%

After Hours: 7:58 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$36.90

Close

$36.52

Volume / Avg.

7.61M / 5.76M

Day Range

$36.46 - $37.39

52 Wk Range

16.26 - 37.35

Market Cap

$42.42B

P/E Ratio

61.23

Dividend Yield

-

Exchange

NYSE

RSI

65

Short Interest

2.96%

Days to Cover

5.74

Recent Teva Pharmaceutical Industries Limited News

Teva's Innovative Drug Portfolio Fuels Growth as Company Raises Outlook, Transitions to Direct NYSE Listing

Teva revenue tops estimates despite an earnings miss. The company raises 2026 sales guidance and highlights strong brand growth.

Vandana Singh

Bill Ackman Says Next $1 Trillion Company Will Come From Israel – ‘Imagine if Silicon Valley Was a Country’

Bill Ackman is bullish on Israel. Here's why he thinks investors should watch the region.

Chris Katje

Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial

Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmentation improvements and favorable safety.

Vandana Singh

Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan

Teva to acquire Emalex for $700 million, posts Q1 earnings beat, and maintains 2026 outlook amid margin and buyback plans.

Vandana Singh

Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda

Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipeline amid bullish analyst targets.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

1.90B

Investing Cash Flow (TTM)

37.00M

Financing Cash Flow (TTM)

-401.00M

Free Cash Flow (TTM)

1.35B

Capital Expenditure (TTM)

-551.00M

Net Change in Cash (TTM)

1.54B

Analyst Trends and Forecast

5

Apr

1

May

1

Jul

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$56.05B

PE Ratio (TTM)

61.23

PE Ratio (FWD)

17.70

PEG Ratio (TTM)

1.01

PS Ratio (TTM)

2.47

PB Ratio (TTM)

5.52

Earnings Yield % (TTM)

1.63%

Earnings Yield % (FWD)

5.65%

EV / EBITDA (TTM)

21.62

Price / EBITDA (TTM)

16.49

Price / Free Cash Flow (TTM)

31.73

Book Value / Share

$6.65

Company Debt

Total Debt

$16.59B

LT Debt

$12.09B

LT Debt Issuance (TTM)

-$7.00M

LT Debt Repayment (TTM)

-$467.00M

Total Cash

$3.66B

Debt to Equity

2.18

Issuance of Debt (TTM)

-$474.00M

Repayment of Debt (TTM)

-$467.00M

Key Statistics

Open

$36.90

Close

$36.52

Volume / Avg.

7.61M / 5.76M

Day Range

$36.46 - $37.39

52 Wk Range

16.26 - 37.35

Market Cap

$42.42B

P/E Ratio

61.23

Dividend Yield

-

Exchange

NYSE

RSI

65

Short Interest

2.96%

Days to Cover

5.74

About

Sector

Health Care

Industry

Pharmaceuticals

Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has ...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Teva Pharmaceutical Indus (TEVA) stock?

A

You can purchase shares of Teva Pharmaceutical Indus (NYSE:TEVA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Teva Pharmaceutical Indus (TEVA) competitors?

A

Other companies in Teva Pharmaceutical Indus’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Teva Pharmaceutical Indus (TEVA) stock?

A

Teva Pharmaceutical Indus has a consensus price target of $35.83.

Q

What is the current price for Teva Pharmaceutical Indus (TEVA)?

A

The stock price for Teva Pharmaceutical Indus (NYSE: TEVA) is $36.4 last updated August 13, 2026 at 7:58 PM EDT.

Q

Does Teva Pharmaceutical Indus (TEVA) pay a dividend?

A

There are no upcoming dividends for Teva Pharmaceutical Indus.

Q

When is Teva Pharmaceutical Indus (NYSE:TEVA) reporting earnings?

A

Teva Pharmaceutical Indus does not have any upcoming earnings scheduled.

Q

Is Teva Pharmaceutical Indus (TEVA) going to split?

A

There is no upcoming split for Teva Pharmaceutical Indus.

Q

What sector and industry does Teva Pharmaceutical Indus (TEVA) operate in?

A

Teva Pharmaceutical Indus is in the Health Care sector and Pharmaceuticals industry. They are listed on the NYSE.